Dow Surges Over 100 Points; Pfizer Earnings Top Views
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 05 2025
0mins
Source: Benzinga
Market Performance: U.S. stocks rose this morning, with the Dow Jones gaining over 100 points, while Pfizer reported better-than-expected earnings and raised its FY 2025 EPS guidance.
Sector Movements: Consumer discretionary shares increased by 0.7%, but energy stocks fell by 0.4%. Notable stock movements included significant gains for SolarMax Technology and Y-mAbs Therapeutics, while Agilon Health saw a drastic decline of 57%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 28.56 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.100
Low
24.00
Averages
28.56
High
35.00
Current: 26.100
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer's Revenue Rebound Potential is Significant
- Revenue Decline: Pfizer projects its 2025 revenue to be between $61 billion and $64 billion, significantly lower than the record-breaking over $100 billion in 2022, indicating challenges in revenue recovery post-COVID-19.
- Shift in Drug Development Focus: The company has struggled to prioritize other drug developments after the success of its COVID-19 vaccine, leading to slow progress in its drug pipeline and impacting overall market competitiveness.
- New Drug Market Potential: Pfizer aims to launch several new billion-dollar oncology drugs by 2030 and has entered a weight-loss drug market through its $10 billion acquisition of Metsera, which could be worth over $150 billion annually, showcasing significant future growth potential.
- Acquisitions Create New Opportunities: The acquisitions of Arena Pharmaceuticals in 2022 and Seagen for $43 billion in 2023 inject new prospects into Pfizer's pipeline, although these new drugs will not complete testing until after 2030, providing hope for future growth despite current challenges.
Continue Reading
ELI LILLY ANNOUNCES PLANS FOR NEW PHARMACEUTICAL MANUFACTURING PLANT IN PENNSYLVANIA
- New Facility Announcement: Eli Lilly has announced plans to build a new pharmaceutical manufacturing facility in Pennsylvania.
- Investment in Manufacturing: This initiative reflects Eli Lilly's commitment to expanding its manufacturing capabilities in the pharmaceutical sector.
Continue Reading